Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

Also called NCT03385538

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03385538
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03385538. Allocation not applicable; no masking; primary purpose prevention. Start 2015-11-01 (actual); primary completion 2017-07-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients
Acronym
CLOGIS
Intervention (Drug)
Clopidogrel
Lead sponsor
Zealand University Hospital (class: other)

Record details

Record id
cardio:ct-nct03385538
Content hash
024ac1ca031a9b7b78e061811558ed3d17a0aa0d64b6db1d8b121b85e79c36d6